AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23475381 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study 23475381 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 32
Study 21244493 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding self‐efficacy intervention
Number of subjects: 150
Study 21244493 — intervention group
Group type: COMPARATOR
Intervention: Standard in‐hospital and community care (Control)
Number of subjects: 150
Study 19497081 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF) implemented in health centres
Number of subjects: 159
Study 16439435 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 10050
Study 14636332 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 0
Study 14636332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10864554 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 10864554 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylureas or Insulin
Number of subjects: 0
Study 8833514 — intervention group
Group type: EXPERIMENTAL
Intervention: Delton light‐polymerized fissure sealant
Number of subjects: 314
Study 8833514 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat fluoride varnish
Number of subjects: 314
Study 8833514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 314
Study 1373956 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) with Kcal/g N2 = 100
Number of subjects: 44
Study 1373956 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) with Kcal/g N2 = 150
Number of subjects: 44
Study 1373956 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with previous PCM
Number of subjects: 44
Study 1373956 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing EG surgery
Number of subjects: 44
Study 1373956 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with gastrointestinal (GI) surgery
Number of subjects: 44
Study 1373956 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with postoperative septic complications (PSC)
Number of subjects: 44
Study 1373956 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative values of albumin (A), prealbumin (PA), and total proteins (TP)
Number of subjects: 44
Study 6487494 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg) + Ethanol (0.5 ml/kg)
Number of subjects: 6
Study 6487494 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg) + Ethanol (0.5 ml/kg)
Number of subjects: 6
Study 6487494 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.5 ml/kg)
Number of subjects: 6
Study 6487494 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Ethanol (0.5 ml/kg)
Number of subjects: 6
Study 6487494 — intervention group
Group type: COMPARATOR
Intervention: Trazodone (100 mg)
Number of subjects: 6
Study 6487494 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (50 mg)
Number of subjects: 6
Study 30358853 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic warning labels
Number of subjects: 925
Study 30358853 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-only warning labels
Number of subjects: 925
Study 30358853 — intervention group
Group type: COMPARATOR
Intervention: Social cue advertisements with the current US Surgeon General's Warning
Number of subjects: 925
Study 28708705 — intervention group
Group type: COMPARATOR
Intervention: Patient-guided (PG) shock wave treatment
Number of subjects: 74
Study 28708705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (UG) shock wave treatment
Number of subjects: 74
Study 25465773 — intervention group
Group type: EXPERIMENTAL
Intervention: DSIG cream
Number of subjects: 130
Study 25465773 — intervention group
Group type: COMPARATOR
Intervention: Topical mouth rinse
Number of subjects: 130
Study 23494116 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (CSI) with methylprednisolone 1 ml
Number of subjects: 138
Study 23494116 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic injection (LAI) with procaine 1 ml 2%
Number of subjects: 138
Study 23494116 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (CSI)
Number of subjects: 138
Study 23494116 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic injection (LAI)
Number of subjects: 138
Study 20663113 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative quality of life measured using Functional Status Index (FSI), Visual Analogue Score (VAS)‐Fatigue, and Functional Assessment of Cancer Therapy Anemia (FACT‐Anemia) subscale
Number of subjects: 603
Study 20663113 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in Hb levels
Number of subjects: 603
Study 19114224 — intervention group
Group type: EXPERIMENTAL
Intervention: Guggul (2160mg daily for 12 weeks)
Number of subjects: 43
Study 19114224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 19114224 — intervention group
Group type: EXPERIMENTAL
Intervention: Guggul
Number of subjects: 43
Study 17548953 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatinose-based balanced formula (PBF)
Number of subjects: 23
Study 17548953 — intervention group
Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 23
Study 17548953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention vs control
Number of subjects: 23
Study 15010623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg orally three times a day after 30 mg ketorolac intravenously every 6 hours until able to take oral medications)
Number of subjects: 100
Study 15010623 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 100
Study 11357169 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-1 receptor antagonist (IL-1ra)
Number of subjects: 0
Study 11357169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7707057 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated military uniforms
Number of subjects: 0
Study 7707057 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated military uniforms
Number of subjects: 0
Study 3300063 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 988
Study 3300063 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-insulinized patients)
Number of subjects: 988
Study 30150152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative periarticular injection (PAI) with liposomal bupivacaine (LB)
Number of subjects: 373
Study 30150152 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 373
Study 26614123 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600 mg)
Number of subjects: 132
Study 26614123 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg)
Number of subjects: 132
Study 26614123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg)
Number of subjects: 132
Study 26394352 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-locator-retained mandibular overdentures
Number of subjects: 30
Study 26394352 — intervention group
Group type: COMPARATOR
Intervention: Two-locator-retained mandibular overdentures
Number of subjects: 30
Study 23939263 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 U of oral cholecalciferol every 3 months for 1 year
Number of subjects: 159
Study 23939263 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 159
Study 21706359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 22
Study 21706359 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib plus topotecan
Number of subjects: 22
Study 18390643 — intervention group
Group type: EXPERIMENTAL
Intervention: Early AMD
Number of subjects: 1361
Study 18390643 — intervention group
Group type: EXPERIMENTAL
Intervention: Late AMD
Number of subjects: 1361
Study 18390643 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft drusen
Number of subjects: 1361
Study 18390643 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft indistinct drusen
Number of subjects: 1361
Study 18390643 — intervention group
Group type: EXPERIMENTAL
Intervention: Any pigmentary change
Number of subjects: 1361
Study 18390643 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 1361
Study 17165276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 100 microg/d
Number of subjects: 145
Study 17165276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 200 microg/d
Number of subjects: 145
Study 17165276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 12614286 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal at day four post-transplantation (n = 40)
Number of subjects: 83
Study 12614286 — intervention group
Group type: COMPARATOR
Intervention: Standard steroid therapy (n = 43)
Number of subjects: 83
Study 12614286 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal group
Number of subjects: 83
Study 12614286 — intervention group
Group type: COMPARATOR
Intervention: Standard steroid therapy group
Number of subjects: 83
Study 12614286 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study 11030295 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid infusion into the lower oesophagus
Number of subjects: 26
Study 11030295 — intervention group
Group type: COMPARATOR
Intervention: Resting oesophageal pain threshold
Number of subjects: 26
Study 10165095 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-assisted weight-loss program (weekly calls)
Number of subjects: 64
Study 10165095 — intervention group
Group type: COMPARATOR
Intervention: Minimal-contact group (no contact)
Number of subjects: 64
Study 8115124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1%
Number of subjects: 20
Study 8115124 — intervention group
Group type: COMPARATOR
Intervention: Tropicamide 1%
Number of subjects: 20
Study 3521526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone sodium plus mezlocillin sodium
Number of subjects: 41
Study 29533358 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric exercises including double‐leg hop, standing long jump, single‐leg standing long jump, bounding, skipping, power skipping, cone hops, and 45.72‐cm hurdle hops.
Number of subjects: 20
Study 29533358 — intervention group
Group type: COMPARATOR
Intervention: Countermovement jump (for comparison).
Number of subjects: 20
Study 29533358 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric exercises (various types).
Number of subjects: 20
Study 29963818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 120
Study 29963818 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 120
Study 29963818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 120
Study 29963818 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (Placebo)
Number of subjects: 120
Study 24755313 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncalcified nodules (NCNs) observed on low-dose computed tomography (LDCT)
Number of subjects: 26272
Study 24755313 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ground-glass attenuation in NCNs
Number of subjects: 26272
Study 24755313 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of noncalcified nodules (NCNs)
Number of subjects: 26272
Study 23001003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent isometric fatigue task at 60% of daily peak force
Number of subjects: 15
Study 23001003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent isometric fatigue task at 70% of daily peak force
Number of subjects: 15
Study 23001003 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived exertion and perceived task duration
Number of subjects: 15
Study 21178138 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-576 (5.0 grams per day, intravenous infusion)
Number of subjects: 0
Study 18081946 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium carbonation (2.5 volumes)
Number of subjects: 30
Study 18081946 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbonation (3.7 volumes)
Number of subjects: 30
Study 18081946 — intervention group
Group type: COMPARATOR
Intervention: Low carbonation (1.7 volumes)
Number of subjects: 30
Study 15990755 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 163
Study 15990755 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy (Control)
Number of subjects: 163
Study 12651043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg) + Aspirin (100 mg)
Number of subjects: 700
Study 12651043 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg) + Aspirin (100 mg)
Number of subjects: 700
Study 10821988 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg/day)
Number of subjects: 72
Study 10821988 — intervention group
Group type: COMPARATOR
Intervention: Methadone (60 mg/day)
Number of subjects: 72
Study 10821988 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 72
Study 10821988 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 72
Study 8695133 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental O2 administered by bag‐valve‐mask during transport, followed by 40% face shield in the PACU
Number of subjects: 100
Study 8695133 — intervention group
Group type: COMPARATOR
Intervention: Supplemental O2 by nasal cannula at 4 L/min during transport and PACU stay
Number of subjects: 100
Study 8257839 — intervention group
Group type: EXPERIMENTAL
Intervention: Suo Quan pill
Number of subjects: 40
Study 8257839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (neutral pill)
Number of subjects: 40
Study 3884080 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ECT
Number of subjects: 19
Study 3884080 — intervention group
Group type: COMPARATOR
Intervention: Simulated ECT
Number of subjects: 19
Study 30614016 — intervention group
Group type: EXPERIMENTAL
Intervention: 585-nm PhotoLase laser
Number of subjects: 18
Study 30614016 — intervention group
Group type: COMPARATOR
Intervention: 532-nm KTP laser
Number of subjects: 18
Study 30614016 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of adverse effects
Number of subjects: 18
Study 30614016 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment speed
Number of subjects: 18
Study 30028929 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured anesthetic gel
Number of subjects: 82
Study 30028929 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 82
Study 27598511 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐mg VILD
Number of subjects: 16
Study 27598511 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLBO)
Number of subjects: 16
Study 25799858 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet as a source of information about the impact of smoking on health
Number of subjects: 160
Study 25799858 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet as a source of information about the impact of alcohol on health
Number of subjects: 160
Study 25799858 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet as a source of information about the impact of energy drinks on health
Number of subjects: 160
Study 25799858 — intervention group
Group type: EXPERIMENTAL
Intervention: Television as a source of information about the impact of smoking on health
Number of subjects: 160
Study 25799858 — intervention group
Group type: EXPERIMENTAL
Intervention: Television as a source of information about the impact of alcohol on health
Number of subjects: 160
Study 25799858 — intervention group
Group type: EXPERIMENTAL
Intervention: Television as a source of information about the impact of energy drinks on health
Number of subjects: 160
Study 23064240 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban 60 mg once daily × 7 days
Number of subjects: 48
Study 23064240 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin 0.25 mg twice daily × 2 days and once daily × 5 days
Number of subjects: 48
Study 23064240 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban and digoxin coadministered for 7 days
Number of subjects: 48
Study 20044531 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA+TCD
Number of subjects: 416
Study 20044531 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA+TCCD
Number of subjects: 416
Study 20044531 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA+low-frequency ultrasound
Number of subjects: 416
Study 20044531 — intervention group
Group type: COMPARATOR
Intervention: tPA alone
Number of subjects: 416
Study 20044531 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA+TCD/TCCD+/−microS
Number of subjects: 416
Study 20044531 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency ultrasound-enhanced thrombolysis
Number of subjects: 416
Study 18320195 — intervention group
Group type: EXPERIMENTAL
Intervention: Water distension
Number of subjects: 83
Study 18320195 — intervention group
Group type: COMPARATOR
Intervention: Air distension
Number of subjects: 83
Study 15759817 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha-1 (T-alpha1) 1.6 mg subcutaneously twice weekly
Number of subjects: 56
Study 15759817 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) 5 million IU daily for 15 days, then thrice weekly for 6 months
Number of subjects: 56
Study 15759817 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (never treated with IFN-alpha)
Number of subjects: 56
Study 15759817 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha-1 (T-alpha1)
Number of subjects: 56
Study 15759817 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 56
Study 12359680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 134
Study 12359680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 10504127 — intervention group
Group type: EXPERIMENTAL
Intervention: AMICUS separator
Number of subjects: 21
Study 10504127 — intervention group
Group type: COMPARATOR
Intervention: Spectra LRS separator
Number of subjects: 21
Study 8708719 — intervention group
Group type: EXPERIMENTAL
Intervention: Western resection with limited (D1) lymphadenectomy
Number of subjects: 237
Study 8708719 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese resection with extended lymphadenectomy (D2)
Number of subjects: 237
Study 8708719 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese surgeon using conventional retrieval
Number of subjects: 237
Study 8708719 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-clearance technique
Number of subjects: 237
Study 1718251 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment of recurrent neovascularization
Number of subjects: 206
Study 1718251 — intervention group
Group type: COMPARATOR
Intervention: No additional laser treatment
Number of subjects: 206
Study 6344038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 199
Study 6344038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 1000 mg
Number of subjects: 199
Study 6344038 — intervention group
Group type: EXPERIMENTAL
Intervention: Zomepirac sodium 100 mg
Number of subjects: 199
Study 6344038 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 199
Study 6344038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 29891331 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 149
Study 29891331 — intervention group
Group type: EXPERIMENTAL
Intervention: High BDNF levels
Number of subjects: 149
Study 29891331 — intervention group
Group type: EXPERIMENTAL
Intervention: CADP-CT >141 s
Number of subjects: 149
Study 29891331 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin concentration >4.22 µg/mL
Number of subjects: 149
Study 29891331 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol and low-density lipoprotein levels
Number of subjects: 149
Study 29958176 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial approach
Number of subjects: 1107
Study 27098538 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial cell preparation
Number of subjects: 40
Study 27098538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24435414 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV and cytology double testing
Number of subjects: 12527
Study 24435414 — intervention group
Group type: COMPARATOR
Intervention: Cytology only
Number of subjects: 12527
Study 24435414 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 12527
Study 24435414 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 12527
Study 23020264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol (10 mg every 5‐10 minutes to a maximum of 80 mg, slowly)
Number of subjects: 90
Study 23020264 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexamethasone (0.15 mg/kg to a maximum of 16 mg, slowly)
Number of subjects: 90
Study 20863004 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg orally for 11 days
Number of subjects: 24
Study 20863004 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg orally for 11 days
Number of subjects: 24
Study 17570119 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 5 mg
Number of subjects: 118
Study 17570119 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 10 mg
Number of subjects: 118
Study 17570119 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 15 mg
Number of subjects: 118
Study 17570119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 16009738 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 1160
Study 16009738 — intervention group
Group type: COMPARATOR
Intervention: Non-hormone therapy (non-HT)
Number of subjects: 1160
Study 12401613 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine 40 mg (Group L)
Number of subjects: 176
Study 12401613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 30 microg/kg (Group E30)
Number of subjects: 176